BACKGROUND: Satraplatin is an oral platinum analog with demonstrated activity in a range of malignancies. The current study was designed to evaluate the effect of varying degrees of renal impairment on the safety and pharmacokinetics (PKs) of satraplatin. PATIENTS AND METHODS: Patients with advanced solid tumors, refractory to standard therapies, were eligible. The study included four cohorts of patients with varying levels of renal function, and eight patients per cohort: Group 1 (G1) = normal renal function; G2 = mild renal impairment [creatinine clearance (CrCl) 50-80 ml/min]; G3 = moderate impairment (CrCl 30 to <50 ml/min); G4 = severe impairment (CrCl <30 ml/min). Satraplatin was administered orally at 80 mg/m(2)/day on days 1-5 every 35 days. RESULTS: A total of 32 patients were enrolled, 8 patients in each renal function group. Each group tolerated the dose of 80 mg/m(2)/day on days 1-5 every 35 days without the need for dose deescalation. The most common adverse events were fatigue (63%), nausea (56%), diarrhea (53%), anorexia (47%), constipation (38%), vomiting (28%), anemia, dyspnea, and thrombocytopenia (25%). There were no dose-limiting toxic effects in any study group. There was increased exposure to plasma platinum and plasma ultrafiltrate platinum in patients with moderate to severe renal impairment. CONCLUSIONS: Satraplatin PKs was altered in patients with renal impairment. However, a corresponding increase in satraplatin-related toxic effects was not observed.
BACKGROUND:Satraplatin is an oral platinum analog with demonstrated activity in a range of malignancies. The current study was designed to evaluate the effect of varying degrees of renal impairment on the safety and pharmacokinetics (PKs) of satraplatin. PATIENTS AND METHODS: Patients with advanced solid tumors, refractory to standard therapies, were eligible. The study included four cohorts of patients with varying levels of renal function, and eight patients per cohort: Group 1 (G1) = normal renal function; G2 = mild renal impairment [creatinine clearance (CrCl) 50-80 ml/min]; G3 = moderate impairment (CrCl 30 to <50 ml/min); G4 = severe impairment (CrCl <30 ml/min). Satraplatin was administered orally at 80 mg/m(2)/day on days 1-5 every 35 days. RESULTS: A total of 32 patients were enrolled, 8 patients in each renal function group. Each group tolerated the dose of 80 mg/m(2)/day on days 1-5 every 35 days without the need for dose deescalation. The most common adverse events were fatigue (63%), nausea (56%), diarrhea (53%), anorexia (47%), constipation (38%), vomiting (28%), anemia, dyspnea, and thrombocytopenia (25%). There were no dose-limiting toxic effects in any study group. There was increased exposure to plasma platinum and plasma ultrafiltrate platinum in patients with moderate to severe renal impairment. CONCLUSIONS:Satraplatin PKs was altered in patients with renal impairment. However, a corresponding increase in satraplatin-related toxic effects was not observed.
Authors: Srivandana Akshintala; Leigh Marcus; Katherine E Warren; Robert F Murphy; Tristan M Sissung; Anjali Srivastava; Wendy J Goodspeed; Anne Goodwin; Carmen C Brewer; Christopher Zalewski; Kelly A King; AeRang Kim; William D Figg; Brigitte C Widemann Journal: Pediatr Blood Cancer Date: 2015-01-03 Impact factor: 3.167
Authors: Ekaterina Schreiber-Brynzak; Verena Pichler; Petra Heffeter; Buck Hanson; Sarah Theiner; Irene Lichtscheidl-Schultz; Christoph Kornauth; Luca Bamonti; Vineet Dhery; Diana Groza; David Berry; Walter Berger; Markus Galanski; Michael A Jakupec; Bernhard K Keppler Journal: Metallomics Date: 2016-02-10 Impact factor: 4.526
Authors: Eugenio Donato Di Paola; Silvia Alonso; Rosa Giuliani; Fabio Calabrò; Antonietta D'Alessio; Giovanni Regine; Linda Cerbone; Laura Bianchi; Andrea Mancuso; Sabine Sperka; Marcel Rozencweig; Cora N Sternberg Journal: Front Oncol Date: 2012-11-22 Impact factor: 6.244